Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
Authors
Keywords
-
Journal
CTS-Clinical and Translational Science
Volume 16, Issue 10, Pages 1911-1922
Publisher
Wiley
Online
2023-08-03
DOI
10.1111/cts.13598
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN U.S. SUBJECTS
- (2022) Loren Laine et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Vonoprazan vs Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
- (2022) Loren Laine et al. GASTROENTEROLOGY
- A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis
- (2022) Daniel Martin Simadibrata et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double‐blind, parallel‐controlled trial
- (2022) Nian‐di Tan et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
- (2021) Deok Y. Yoon et al. CTS-Clinical and Translational Science
- Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial
- (2021) Daisuke Kawai et al. BMC GASTROENTEROLOGY
- Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan
- (2021) Sungpil Han et al. CLINICAL THERAPEUTICS
- The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
- (2021) Darcy J. Mulford et al. Clinical Pharmacology in Drug Development
- Randomized clinical trial: 7‐day vonoprazan‐based versus 14‐day omeprazole‐based triple therapy for Helicobacter pylori
- (2021) Chalermrat Bunchorntavakul et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Potential proton pump inhibitor–related adverse effects
- (2020) Issac E. Perry et al. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
- Pharmacologic treatment of GERD: Where we are now, and where are we going?
- (2020) Carmelo Scarpignato et al. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
- Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects
- (2020) Jinjie He et al. CLINICAL DRUG INVESTIGATION
- Diagnosis and Treatment of Peptic Ulcer Disease
- (2019) Robert T. Kavitt et al. AMERICAN JOURNAL OF MEDICINE
- Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects
- (2019) Sungpil Han et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects
- (2018) J. Sunwoo et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Presentation and Epidemiology of Gastroesophageal Reflux Disease
- (2018) Joel E. Richter et al. GASTROENTEROLOGY
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- (2018) Yoshikazu Kinoshita et al. Journal of Neurogastroenterology and Motility
- Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
- (2018) Tadayuki Oshima et al. Journal of Neurogastroenterology and Motility
- KFP-H008 blocks gastric acid secretion through inhibiting H + -K + -ATPase
- (2017) Cheng-yuan Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis
- (2017) Leonardo H Eusebi et al. GUT
- Peptic ulcer disease
- (2017) Angel Lanas et al. LANCET
- Gastroesophageal Reflux Disease
- (2017) Rick Kellerman et al. PRIMARY CARE
- Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
- (2015) H. Jenkins et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study
- (2015) Y. Sakurai et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
- (2015) Hirotoshi Echizen CLINICAL PHARMACOKINETICS
- Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
- (2013) Jai Moo Shin et al. Journal of Neurogastroenterology and Motility
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search